首页
订购/客服:400-666-5481

Ki20227

    
≥98%

Ki20227

源叶(MedMol)
S85999 一键复制产品信息
623142-96-1
C24H24N4O5S
480.55
货号 规格 价格 上海 北京 珠海 重庆 武汉 购买数量
S85999-2mg
≥98%

¥520.00

5 - - - -
S85999-5mg
≥98%

¥890.00

6 - - - -
S85999-10mg
≥98%

¥1290.00

6 - - - -
S85999-50mg
≥98%

¥3860.00

8 - - - -
产品介绍 参考文献 质检证书(COA) 摩尔浓度计算器 相关产品
产品描述: Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction
靶点: IC50: 2 nM (CSF1R), 12 nM (VEGFR2), 451 nM (c-Kit) and 217 nM (PDGFRβ);c-Fms;VEGFR;CSF-1R;PDGFR;c-Kit
体内研究: Ki20227 (orally;10-50 mg/kg/d for 20 days) of 50 mg/kg/d of Ki20227 for 20 days markedly decreases the osteolytic lesion areas. ki20227 during global ischemia led to a significant deficit in microglial density in the CNS in mice, and CSF1R-inhibition led to a significant reduction in the neuronal density of mice
参考文献: 1. Ohno H, et al. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43. 2. Boru Hou, et al. Ki20227 influences the morphology of microglia and neurons through inhibition of CSF1R during global ischemia. Int J Clin Exp Pathol. 2016;9(12):12459-12469.
溶解性: Soluble  in  DMSO
保存条件: -20℃
配置溶液浓度参考:
1mg 5mg 10mg
1 mM 2.081 ml 10.405 ml 20.809 ml
5 mM 0.416 ml 2.081 ml 4.162 ml
10 mM 0.208 ml 1.04 ml 2.081 ml
50 mM 0.042 ml 0.208 ml 0.416 ml
注意: 部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。

参考文献

质检证书(COA)

如何获取质检证书(COA)?
请输入货号和一个与之匹配的批号。
例如:
批号:JS298415 货号:S20001-25g
在货品标签上如何找到货号和批号?

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)

=
×
×